Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LUCD Stock Summary
Top 10 Correlated ETFs
LUCD
In the News
Lucid Diagnostics Inc. (LUCD) Q3 2023 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2023 Results Conference Call November 14, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode.
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced its Chairman and Chief Executive Officer, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023 at 10:00am EST in New York City.
Lucid Diagnostics Inc. (LUCD) Q2 2023 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Ed Woo - Ascendiant Capital Kyle Mikson - Canaccord Mark Massaro - BTIG Mike Matson - Needham & Co. Operator Good day, and welcome to the Lucid Diagnostics Second Quarter 2023 Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded.
Lucid Diagnostics Inc. (LUCD) Q1 2023 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2023 Results Conference Call May 16, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Alex Vukasin - Canaccord Genuity Mike Matson - Needham Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.
Lucid to cut 1,300 workers amid signs of flagging demand for its EVs
Lucid CEO Peter Rawlinson said the job cuts will hit "nearly every organization and level, including executives."
Lucid Diagnostics Inc. (LUCD) Q4 2022 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2022 Earnings Conference Call March 14, 2023 8:30 AM ET Company Participants Michael Parks - Vice President, Investor Relations Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co. Mark Massaro - BTIG Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants will be in a listen-only mode.
Lucid Diagnostics Inc. (LUCD) Q3 2022 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Ross Osborn - Cantor Fitzgerald Ed Woo - Ascendiant Capital Greetings, and welcome to Lucid Diagnostics Third Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT.
Lucid Diagnostics Inc. (LUCD) CEO Lishan Aklog on Q2 2022 Results - Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Company Ed Woo - Ascendiant Capital Mark Massaro - BTIG Operator Greetings, and welcome to Lucid Diagnostics Second Quarter 2020 Business Update Conference Call. At this time, all participants are in a listen-only mode.
LUCD Financial details
LUCD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.03 | 0.01 | |
Net income per share | -0.12 | -0.22 | -1.54 | -1.55 | |
Operating cash flow per share | -0.06 | -0.15 | -0.95 | -0.82 | |
Free cash flow per share | -0.06 | -0.15 | -1 | -0.85 | |
Cash per share | 0.01 | 0.01 | 2.94 | 0.66 | |
Book value per share | -0.14 | -0.37 | 2.94 | 0.64 | |
Tangible book value per share | -0.14 | -0.37 | 2.94 | 0.54 | |
Share holders equity per share | -0.14 | -0.37 | 2.94 | 0.64 | |
Interest debt per share | 0 | 0 | 0.04 | 0.06 | |
Market cap | 435.03M | 435.03M | 99.9M | 49.19M | |
Enterprise value | 434.87M | 434.92M | 46.25M | 28.72M | |
P/E ratio | -98.41 | -52.54 | -3.48 | -0.88 | |
Price to sales ratio | 0 | 0 | 199.8 | 130.49 | |
POCF ratio | -184.22 | -77.29 | -5.65 | -1.66 | |
PFCF ratio | -184.22 | -77.29 | -5.39 | -1.61 | |
P/B Ratio | -81.94 | -32.18 | 1.83 | 2.13 | |
PTB ratio | -81.94 | -32.18 | 1.83 | 2.13 | |
EV to sales | 0 | 0 | 92.49 | 76.18 | |
Enterprise value over EBITDA | -98.37 | -52.53 | -1.69 | -0.53 | |
EV to operating cash flow | -184.16 | -77.27 | -2.62 | -0.97 | |
EV to free cash flow | -184.16 | -77.27 | -2.5 | -0.94 | |
Earnings yield | -0.01 | -0.02 | -0.29 | -1.14 | |
Free cash flow yield | -0.01 | -0.01 | -0.19 | -0.62 | |
Debt to equity | 0 | 0 | 0 | 0.09 | |
Debt to assets | 0 | 0 | 0 | 0.06 | |
Net debt to EBITDA | 0.04 | 0.01 | 1.96 | 0.38 | |
Current ratio | 0.06 | 0.09 | 13.45 | 2.89 | |
Interest coverage | 0 | 0 | -41.61 | 0 | |
Income quality | 0.53 | 0.68 | 0.63 | 0.53 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 25.56 | 62.82 | |
Research and developement to revenue | 0 | 0 | 18.59 | 30.41 | |
Intangibles to total assets | 0 | 0 | 0 | 0.11 | |
Capex to operating cash flow | 0 | 0 | 0.05 | 0.03 | |
Capex to revenue | 0 | 0 | -1.72 | -2.41 | |
Capex to depreciation | 0 | 0 | -215.5 | -0.47 | |
Stock based compensation to revenue | 0 | 0 | 19.2 | 39.76 | |
Graham number | 0.62 | 1.36 | 10.11 | 4.72 | |
ROIC | 0 | 0 | -0.51 | -2.08 | |
Return on tangible assets | -4.28 | -3.77 | -0.49 | -1.93 | |
Graham Net | -0.16 | -0.41 | 2.74 | 0.4 | |
Working capital | -5.95M | -14.27M | 53.04M | 15.93M | |
Tangible asset value | -5.31M | -13.52M | 54.74M | 19.6M | |
Net current asset value | -5.95M | -14.27M | 53.04M | 14.89M | |
Invested capital | 0 | 0 | 0 | 0.09 | |
Average receivables | 0 | 0.5 | 100K | 108.5K | |
Average payables | 0 | 1.43M | 1.77M | 1.27M | |
Average inventory | 0 | 416.88K | 663.38K | 302K | |
Days sales outstanding | 0 | 0 | 146 | 16.46 | |
Days payables outstanding | 0 | 0 | 929.66 | 106.65 | |
Days of inventory on hand | 0 | 0 | 307.6 | 11.21 | |
Receivables turnover | 0 | 0 | 2.5 | 22.18 | |
Payables turnover | 0 | 0 | 0.39 | 3.42 | |
Inventory turnover | 0 | 0 | 1.19 | 32.56 | |
ROE | 0.83 | 0.61 | -0.52 | -2.44 | |
Capex per share | 0 | 0 | -0.05 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.01 | 0 | 0.02 | |
Net income per share | -0.39 | -0.41 | -48.31 | -0.27 | -0.34 | |
Operating cash flow per share | -0.17 | -0.12 | -0.17 | -0.17 | -0.21 | |
Free cash flow per share | -0.18 | -0.12 | -0.17 | -0.17 | -0.21 | |
Cash per share | 0.81 | 0.66 | 1.01 | 0.84 | 0.57 | |
Book value per share | 0.76 | 0.64 | 0.61 | 0.36 | 0.06 | |
Tangible book value per share | 0.65 | 0.54 | 0.54 | 0.3 | 0.01 | |
Share holders equity per share | 0.76 | 0.64 | 0.61 | 0.36 | 0.06 | |
Interest debt per share | 0.06 | 0.05 | 0.34 | 0.33 | 0.39 | |
Market cap | 55.7M | 49.19M | 57.36M | 58.15M | 48.98M | |
Enterprise value | 30.77M | 28.72M | 31.61M | 39.02M | 41.01M | |
P/E ratio | -0.97 | -0.83 | -0.01 | -1.28 | -0.86 | |
Price to sales ratio | 732.91 | 439.24 | 128.61 | 365.72 | 62.55 | |
POCF ratio | -8.78 | -11.55 | -8.14 | -8.29 | -5.58 | |
PFCF ratio | -8.35 | -11.03 | -8.12 | -8.28 | -5.57 | |
P/B Ratio | 2.02 | 2.13 | 2.3 | 3.86 | 19.16 | |
PTB ratio | 2.02 | 2.13 | 2.3 | 3.86 | 19.16 | |
EV to sales | 404.87 | 256.42 | 70.88 | 245.41 | 52.38 | |
Enterprise value over EBITDA | -2.24 | -2.01 | -2.03 | -3.61 | -3.06 | |
EV to operating cash flow | -4.85 | -6.74 | -4.49 | -5.56 | -4.67 | |
EV to free cash flow | -4.62 | -6.44 | -4.48 | -5.55 | -4.66 | |
Earnings yield | -0.26 | -0.3 | -34.51 | -0.2 | -0.29 | |
Free cash flow yield | -0.12 | -0.09 | -0.12 | -0.12 | -0.18 | |
Debt to equity | 0.07 | 0.09 | 0.55 | 0.89 | 6.29 | |
Debt to assets | 0.05 | 0.06 | 0.28 | 0.32 | 0.48 | |
Net debt to EBITDA | 1.81 | 1.43 | 1.65 | 1.77 | 0.59 | |
Current ratio | 3.08 | 2.89 | 1.78 | 1.34 | 0.9 | |
Interest coverage | 0 | 86.29 | -433.85 | -51.95 | -74.68 | |
Income quality | 0.44 | 0.29 | 0.43 | 0.62 | 0.62 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 74.47 | 48.77 | 14.6 | 24.09 | 5.52 | |
Research and developement to revenue | 35.58 | 21.8 | 5.12 | 11.49 | 2.06 | |
Intangibles to total assets | 0.1 | 0.11 | 0.06 | 0.06 | 0.06 | |
Capex to operating cash flow | 0.05 | 0.05 | 0 | 0 | 0 | |
Capex to revenue | -4.22 | -1.81 | -0.04 | -0.09 | -0.02 | |
Capex to depreciation | -0.54 | -0.33 | -0.03 | -0.02 | -0.02 | |
Stock based compensation to revenue | 47 | 33.39 | 7.19 | 8.8 | 1.6 | |
Graham number | 2.59 | 2.42 | 25.71 | 1.48 | 0.68 | |
ROIC | -0.45 | -0.55 | -43 | -0.39 | -0.44 | |
Return on tangible assets | -0.42 | -0.51 | -42.85 | -0.28 | -0.45 | |
Graham Net | 0.51 | 0.4 | 0.42 | 0.19 | -0.16 | |
Working capital | 20.15M | 15.93M | 18.33M | 9.07M | -2.92M | |
Tangible asset value | 23.58M | 19.6M | 21.97M | 12.64M | 627K | |
Net current asset value | 19M | 14.89M | 17.5M | 8.33M | -3.39M | |
Invested capital | 0.07 | 0.09 | 0.55 | 0.89 | 6.29 | |
Average receivables | 15.5K | 24K | 22K | 31K | 28K | |
Average payables | 1.75M | 1.08M | 840.5K | 631K | 815.5K | |
Average inventory | 192K | 107.5K | 86.5K | 52K | 116K | |
Days sales outstanding | 36.71 | 13.66 | 5.45 | 19.81 | 2.41 | |
Days payables outstanding | 61 | 58.74 | 42.04 | 37.01 | 54.75 | |
Days of inventory on hand | 5.76 | 6.17 | 4.17 | 2.44 | 10.47 | |
Receivables turnover | 2.45 | 6.59 | 16.52 | 4.54 | 37.29 | |
Payables turnover | 1.48 | 1.53 | 2.14 | 2.43 | 1.64 | |
Inventory turnover | 15.63 | 14.58 | 21.58 | 36.88 | 8.6 | |
ROE | -0.52 | -0.64 | -79.47 | -0.76 | -5.56 | |
Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
LUCD Frequently Asked Questions
What is Lucid Diagnostics Inc. stock symbol ?
Lucid Diagnostics Inc. is a US stock , located in New york of Ny and trading under the symbol LUCD
Is Lucid Diagnostics Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $3.3. The lowest prediction is $3.1 and the highest is $3.5
What is LUCD stock prediction ?
What is Lucid Diagnostics Inc. stock quote today ?
Lucid Diagnostics Inc. stock price is $0.8099 today.
Is Lucid Diagnostics Inc. stock public?
Yes, Lucid Diagnostics Inc. is a publicly traded company.